Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flinn

Showing results (941-950 of 1,038) with videos related to

Pageof 104
Sort By:
Biorxiv : the Preprint Server for Biology|May 15, 2024
Cysteine Rich Intestinal Protein 2 is a copper-responsive regulator of skeletal muscle differentiationOdette Verdejo-Torres, David C Klein, Lorena Novoa-Aponte, et al.
Journal of Affective Disorders|March 24, 2023
Comparative effectiveness of two versions of a caring contacts intervention in healthcare providers, staff, and patients for reducing loneliness and mental distress: A randomized controlled trialAnna K Radin, Jenny Shaw, Siobhan P Brown, et al.
Pediatrics|March 15, 2026
Clinical Practice Guideline for Diagnosis and Management of Faltering WeightHans B Kersten, Praveen S Goday, Ruba Abdelhadi, et al.
Leukemia|January 8, 2021
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysisHagop M Kantarjian, Timothy P Hughes, Richard A Larson, et al.
Leukemia|June 10, 2021
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysisHagop M Kantarjian, Timothy P Hughes, Richard A Larson, et al.
The New England Journal of Medicine|November 1, 2018
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's LymphomaRanjana Advani, Ian Flinn, Leslie Popplewell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2019
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent LymphomaJohn P Leonard, Marek Trneny, Koji Izutsu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2017
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell LymphomaJohn P Leonard, Kathryn S Kolibaba, James A Reeves, et al.
Cancer Genetics|October 14, 2017
Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignanciesSandeep Mukherjee, Malini Sathanoori, Zeq Ma, et al.
Ejhaem|July 18, 2022
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphomaVincent Ribrag, Julio C Chavez, Carola Boccomini, et al.
Pageof 104

Showing results (941-950 of 1,038) with videos related to

Sort By:
Pageof 104
Biorxiv : the Preprint Server for Biology|May 15, 2024
Cysteine Rich Intestinal Protein 2 is a copper-responsive regulator of skeletal muscle differentiationOdette Verdejo-Torres, David C Klein, Lorena Novoa-Aponte, et al.
Journal of Affective Disorders|March 24, 2023
Comparative effectiveness of two versions of a caring contacts intervention in healthcare providers, staff, and patients for reducing loneliness and mental distress: A randomized controlled trialAnna K Radin, Jenny Shaw, Siobhan P Brown, et al.
Pediatrics|March 15, 2026
Clinical Practice Guideline for Diagnosis and Management of Faltering WeightHans B Kersten, Praveen S Goday, Ruba Abdelhadi, et al.
Leukemia|January 8, 2021
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysisHagop M Kantarjian, Timothy P Hughes, Richard A Larson, et al.
Leukemia|June 10, 2021
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysisHagop M Kantarjian, Timothy P Hughes, Richard A Larson, et al.
The New England Journal of Medicine|November 1, 2018
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's LymphomaRanjana Advani, Ian Flinn, Leslie Popplewell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2019
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent LymphomaJohn P Leonard, Marek Trneny, Koji Izutsu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2017
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell LymphomaJohn P Leonard, Kathryn S Kolibaba, James A Reeves, et al.
Cancer Genetics|October 14, 2017
Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignanciesSandeep Mukherjee, Malini Sathanoori, Zeq Ma, et al.
Ejhaem|July 18, 2022
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphomaVincent Ribrag, Julio C Chavez, Carola Boccomini, et al.
Pageof 104